BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study

BioDelivery Sciences International, Inc. BDSI announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the trial.